| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community Health Services | 10 | 2018 | 657 | 1.390 |
Why?
|
| Haiti | 28 | 2022 | 553 | 1.280 |
Why?
|
| Lesotho | 11 | 2025 | 77 | 1.170 |
Why?
|
| HIV Infections | 38 | 2018 | 17530 | 1.130 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 17 | 2023 | 942 | 0.960 |
Why?
|
| Qualitative Research | 7 | 2025 | 3135 | 0.930 |
Why?
|
| International Cooperation | 8 | 2020 | 1432 | 0.890 |
Why?
|
| Rural Population | 15 | 2022 | 2317 | 0.860 |
Why?
|
| Antitubercular Agents | 16 | 2023 | 1382 | 0.850 |
Why?
|
| Fluorine Radioisotopes | 9 | 1999 | 398 | 0.770 |
Why?
|
| Health Care Reform | 3 | 2025 | 1258 | 0.730 |
Why?
|
| Public Policy | 2 | 2022 | 551 | 0.710 |
Why?
|
| Resource Allocation | 2 | 2020 | 354 | 0.700 |
Why?
|
| Health Planning Organizations | 1 | 2019 | 13 | 0.650 |
Why?
|
| Leiomyoma | 2 | 2022 | 644 | 0.650 |
Why?
|
| Medical Assistance | 1 | 2020 | 109 | 0.640 |
Why?
|
| Primary Health Care | 6 | 2025 | 4735 | 0.630 |
Why?
|
| Organizational Objectives | 2 | 2019 | 426 | 0.620 |
Why?
|
| Delivery of Health Care | 10 | 2023 | 5368 | 0.610 |
Why?
|
| Monoamine Oxidase Inhibitors | 4 | 1999 | 152 | 0.610 |
Why?
|
| Social Support | 8 | 2016 | 2191 | 0.600 |
Why?
|
| Monoamine Oxidase | 4 | 1999 | 179 | 0.600 |
Why?
|
| Anti-HIV Agents | 13 | 2018 | 4558 | 0.600 |
Why?
|
| Health Services Accessibility | 13 | 2022 | 5508 | 0.590 |
Why?
|
| Refugees | 3 | 2022 | 615 | 0.580 |
Why?
|
| Directly Observed Therapy | 8 | 2018 | 139 | 0.580 |
Why?
|
| Developing Countries | 14 | 2020 | 2913 | 0.570 |
Why?
|
| Health Plan Implementation | 2 | 2021 | 338 | 0.570 |
Why?
|
| Population Growth | 1 | 2016 | 50 | 0.540 |
Why?
|
| Tuberculosis, Pulmonary | 6 | 2014 | 837 | 0.520 |
Why?
|
| Birth Rate | 1 | 2016 | 168 | 0.490 |
Why?
|
| Child Mortality | 3 | 2014 | 204 | 0.480 |
Why?
|
| Rural Health | 3 | 2006 | 301 | 0.480 |
Why?
|
| Human Rights | 4 | 2022 | 312 | 0.470 |
Why?
|
| Hemorrhagic Fever, Ebola | 2 | 2016 | 424 | 0.470 |
Why?
|
| Tomography, Emission-Computed | 11 | 1999 | 1006 | 0.430 |
Why?
|
| Maternal Health Services | 2 | 2024 | 472 | 0.430 |
Why?
|
| Communicable Disease Control | 5 | 2020 | 856 | 0.420 |
Why?
|
| Community Health Planning | 1 | 2013 | 164 | 0.420 |
Why?
|
| Caregivers | 4 | 2015 | 2304 | 0.390 |
Why?
|
| Receptors, Dopamine D2 | 5 | 1999 | 471 | 0.390 |
Why?
|
| Maternal Welfare | 1 | 2012 | 113 | 0.390 |
Why?
|
| Uterine Neoplasms | 1 | 2021 | 1425 | 0.380 |
Why?
|
| Anti-Retroviral Agents | 5 | 2012 | 1786 | 0.380 |
Why?
|
| Health Priorities | 3 | 2020 | 382 | 0.370 |
Why?
|
| Medication Adherence | 4 | 2018 | 2190 | 0.360 |
Why?
|
| Women's Rights | 1 | 2011 | 66 | 0.360 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2010 | 30 | 0.360 |
Why?
|
| Fluoxetine | 3 | 1999 | 731 | 0.350 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 3925 | 0.340 |
Why?
|
| Poverty Areas | 3 | 2006 | 268 | 0.340 |
Why?
|
| HIV | 3 | 2013 | 1585 | 0.330 |
Why?
|
| Sierra Leone | 4 | 2024 | 171 | 0.330 |
Why?
|
| Rural Health Services | 6 | 2014 | 393 | 0.330 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2011 | 1353 | 0.330 |
Why?
|
| Public Health | 1 | 2022 | 2678 | 0.310 |
Why?
|
| Interviews as Topic | 4 | 2025 | 2741 | 0.310 |
Why?
|
| HIV Seropositivity | 4 | 2014 | 961 | 0.300 |
Why?
|
| Civil Disorders | 1 | 2008 | 8 | 0.300 |
Why?
|
| Humans | 113 | 2025 | 765823 | 0.300 |
Why?
|
| Harm Reduction | 1 | 2009 | 141 | 0.290 |
Why?
|
| Reproductive Medicine | 1 | 2009 | 96 | 0.290 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2010 | 2204 | 0.280 |
Why?
|
| Blood Specimen Collection | 1 | 2008 | 238 | 0.280 |
Why?
|
| Poverty | 10 | 2021 | 2714 | 0.280 |
Why?
|
| Antiretroviral Therapy, Highly Active | 10 | 2012 | 1899 | 0.280 |
Why?
|
| Rwanda | 9 | 2018 | 671 | 0.270 |
Why?
|
| Tuberculosis | 6 | 2023 | 2013 | 0.260 |
Why?
|
| Narration | 1 | 2008 | 223 | 0.260 |
Why?
|
| Politics | 2 | 2024 | 821 | 0.250 |
Why?
|
| Adolescent Behavior | 2 | 2015 | 1185 | 0.250 |
Why?
|
| Family | 4 | 2015 | 3208 | 0.250 |
Why?
|
| Pyrrolidines | 2 | 1999 | 337 | 0.250 |
Why?
|
| Government Programs | 3 | 2019 | 278 | 0.250 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 1999 | 490 | 0.240 |
Why?
|
| Cajanus | 1 | 2024 | 2 | 0.230 |
Why?
|
| Health Facilities | 2 | 2022 | 577 | 0.230 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 144 | 0.230 |
Why?
|
| RNA, Plant | 1 | 2024 | 30 | 0.230 |
Why?
|
| World Health Organization | 3 | 2022 | 1326 | 0.230 |
Why?
|
| Family Characteristics | 1 | 2009 | 1001 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2011 | 2184 | 0.220 |
Why?
|
| Hypertension | 1 | 2024 | 8625 | 0.220 |
Why?
|
| Receptors, Dopamine D1 | 2 | 1996 | 276 | 0.220 |
Why?
|
| Medical Records Systems, Computerized | 3 | 2004 | 1195 | 0.220 |
Why?
|
| Gram-Positive Bacteria | 1 | 2004 | 180 | 0.210 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2024 | 208 | 0.210 |
Why?
|
| Drug Approval | 1 | 2010 | 818 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 550 | 0.210 |
Why?
|
| Clorgyline | 2 | 1999 | 13 | 0.210 |
Why?
|
| Benzazepines | 2 | 1996 | 308 | 0.210 |
Why?
|
| Chlamydia Infections | 1 | 2006 | 364 | 0.200 |
Why?
|
| Vulnerable Populations | 3 | 2017 | 718 | 0.200 |
Why?
|
| Violence | 1 | 2008 | 934 | 0.200 |
Why?
|
| Depressive Disorder | 2 | 2017 | 3711 | 0.190 |
Why?
|
| Organizational Case Studies | 3 | 2020 | 300 | 0.190 |
Why?
|
| Gonorrhea | 1 | 2006 | 354 | 0.190 |
Why?
|
| Social Stigma | 3 | 2014 | 787 | 0.190 |
Why?
|
| Benzamides | 2 | 1999 | 1376 | 0.190 |
Why?
|
| Sexual Partners | 4 | 2010 | 804 | 0.190 |
Why?
|
| Women's Health | 1 | 2011 | 2082 | 0.190 |
Why?
|
| Medically Underserved Area | 1 | 2003 | 267 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 12 | 1999 | 8105 | 0.180 |
Why?
|
| Female | 50 | 2025 | 396050 | 0.180 |
Why?
|
| Patient Compliance | 4 | 2012 | 2693 | 0.180 |
Why?
|
| National Health Programs | 2 | 2019 | 443 | 0.170 |
Why?
|
| Health Resources | 2 | 2003 | 949 | 0.170 |
Why?
|
| Dextroamphetamine | 2 | 1997 | 132 | 0.170 |
Why?
|
| Students | 1 | 2009 | 1739 | 0.170 |
Why?
|
| Malawi | 4 | 2023 | 313 | 0.160 |
Why?
|
| Depression | 5 | 2017 | 8224 | 0.160 |
Why?
|
| Radiopharmaceuticals | 2 | 1999 | 2700 | 0.160 |
Why?
|
| Health Promotion | 2 | 2011 | 2208 | 0.160 |
Why?
|
| Quality of Life | 1 | 2021 | 13466 | 0.160 |
Why?
|
| Maternal Mortality | 2 | 2012 | 310 | 0.160 |
Why?
|
| Financing, Organized | 1 | 2020 | 201 | 0.150 |
Why?
|
| Health Services Administration | 2 | 2017 | 63 | 0.150 |
Why?
|
| Uridine Monophosphate | 1 | 2018 | 67 | 0.150 |
Why?
|
| Disease Outbreaks | 4 | 2022 | 1760 | 0.150 |
Why?
|
| Earthquakes | 1 | 2021 | 192 | 0.150 |
Why?
|
| Propylamines | 1 | 1999 | 161 | 0.150 |
Why?
|
| Peru | 6 | 2008 | 887 | 0.150 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 1405 | 0.150 |
Why?
|
| Male | 47 | 2025 | 363740 | 0.150 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 2 | 2008 | 85 | 0.150 |
Why?
|
| Health Policy | 5 | 2014 | 2699 | 0.140 |
Why?
|
| Fluorenes | 1 | 2018 | 160 | 0.140 |
Why?
|
| Socioeconomic Factors | 3 | 2010 | 7840 | 0.140 |
Why?
|
| Consumer Advocacy | 2 | 2011 | 83 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2004 | 742 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2006 | 1216 | 0.140 |
Why?
|
| Parents | 2 | 2015 | 3590 | 0.140 |
Why?
|
| Pregnancy | 9 | 2024 | 30215 | 0.140 |
Why?
|
| Social Responsibility | 1 | 2020 | 382 | 0.140 |
Why?
|
| Health Personnel | 4 | 2024 | 3386 | 0.140 |
Why?
|
| Brain | 10 | 1999 | 27178 | 0.140 |
Why?
|
| House Calls | 1 | 2018 | 171 | 0.130 |
Why?
|
| Drug Costs | 2 | 2004 | 1193 | 0.130 |
Why?
|
| Liberia | 1 | 2016 | 176 | 0.130 |
Why?
|
| Salicylamides | 1 | 1996 | 31 | 0.130 |
Why?
|
| Program Development | 3 | 2014 | 1296 | 0.130 |
Why?
|
| Rats | 12 | 1999 | 23707 | 0.130 |
Why?
|
| Education, Medical, Graduate | 2 | 2021 | 2418 | 0.130 |
Why?
|
| Pandemics | 4 | 2022 | 8698 | 0.120 |
Why?
|
| Adult | 30 | 2024 | 223055 | 0.120 |
Why?
|
| Fees and Charges | 1 | 2016 | 189 | 0.120 |
Why?
|
| Financing, Government | 1 | 2019 | 473 | 0.120 |
Why?
|
| Program Evaluation | 7 | 2018 | 2501 | 0.120 |
Why?
|
| Antiviral Agents | 2 | 2018 | 3051 | 0.120 |
Why?
|
| Rape | 2 | 2007 | 131 | 0.120 |
Why?
|
| United Nations | 3 | 2011 | 151 | 0.120 |
Why?
|
| Binding, Competitive | 4 | 1998 | 1140 | 0.120 |
Why?
|
| Parent-Child Relations | 2 | 2010 | 774 | 0.120 |
Why?
|
| Education, Nursing, Diploma Programs | 1 | 2014 | 11 | 0.120 |
Why?
|
| Malnutrition | 1 | 2021 | 628 | 0.120 |
Why?
|
| Radioligand Assay | 4 | 1999 | 364 | 0.120 |
Why?
|
| Population Dynamics | 1 | 2016 | 314 | 0.120 |
Why?
|
| Social Medicine | 1 | 2015 | 64 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 2 | 2007 | 255 | 0.110 |
Why?
|
| Tissue Distribution | 5 | 1999 | 2270 | 0.110 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 26276 | 0.110 |
Why?
|
| Mali | 1 | 2013 | 51 | 0.110 |
Why?
|
| Macaca mulatta | 7 | 1999 | 2341 | 0.110 |
Why?
|
| Ebolavirus | 1 | 2016 | 250 | 0.110 |
Why?
|
| Autoradiography | 3 | 1999 | 723 | 0.110 |
Why?
|
| Retrospective Studies | 18 | 2024 | 81505 | 0.110 |
Why?
|
| Critical Illness | 2 | 2023 | 2745 | 0.110 |
Why?
|
| Adaptation, Psychological | 3 | 2015 | 2662 | 0.110 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 391 | 0.110 |
Why?
|
| Corpus Striatum | 2 | 1999 | 1218 | 0.110 |
Why?
|
| Quality Improvement | 2 | 2023 | 3845 | 0.110 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 123 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2018 | 863 | 0.110 |
Why?
|
| Internal-External Control | 1 | 2015 | 348 | 0.110 |
Why?
|
| Learning | 1 | 2022 | 1754 | 0.110 |
Why?
|
| Intensive Care Units | 2 | 2023 | 3799 | 0.100 |
Why?
|
| Hospitals | 2 | 2023 | 3887 | 0.100 |
Why?
|
| Health Services Research | 2 | 2017 | 1811 | 0.100 |
Why?
|
| Nurse Midwives | 1 | 2012 | 24 | 0.100 |
Why?
|
| Uganda | 2 | 2008 | 1353 | 0.100 |
Why?
|
| Education, Nursing | 1 | 2012 | 84 | 0.100 |
Why?
|
| Personnel, Hospital | 1 | 2014 | 285 | 0.100 |
Why?
|
| HIV Seronegativity | 2 | 2010 | 209 | 0.100 |
Why?
|
| Glycemic Index | 1 | 2014 | 400 | 0.100 |
Why?
|
| Inservice Training | 1 | 2014 | 374 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2009 | 4627 | 0.090 |
Why?
|
| Child, Orphaned | 1 | 2012 | 55 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 123 | 0.090 |
Why?
|
| Healthy People Programs | 1 | 2011 | 54 | 0.090 |
Why?
|
| Mother-Child Relations | 1 | 2014 | 499 | 0.090 |
Why?
|
| Midwifery | 1 | 2012 | 131 | 0.090 |
Why?
|
| Epidemics | 1 | 2016 | 513 | 0.090 |
Why?
|
| Truth Disclosure | 1 | 2014 | 433 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2018 | 1032 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2012 | 194 | 0.090 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2010 | 43 | 0.090 |
Why?
|
| Viral Load | 6 | 2018 | 3385 | 0.090 |
Why?
|
| Curriculum | 2 | 2021 | 3780 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2022 | 42478 | 0.090 |
Why?
|
| Child Development | 1 | 2022 | 2327 | 0.080 |
Why?
|
| Research Design | 1 | 2006 | 6207 | 0.080 |
Why?
|
| Occupations | 2 | 2010 | 516 | 0.080 |
Why?
|
| Russia | 5 | 2008 | 383 | 0.080 |
Why?
|
| Adolescent | 15 | 2017 | 88794 | 0.080 |
Why?
|
| Risk Factors | 8 | 2021 | 74853 | 0.080 |
Why?
|
| Child Welfare | 1 | 2013 | 521 | 0.080 |
Why?
|
| Infant | 6 | 2022 | 36375 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2004 | 592 | 0.080 |
Why?
|
| RNA, Messenger | 1 | 2024 | 12767 | 0.080 |
Why?
|
| Meningitis | 1 | 2010 | 217 | 0.080 |
Why?
|
| Treatment Outcome | 14 | 2018 | 65223 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2018 | 2586 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2015 | 877 | 0.080 |
Why?
|
| Healthcare Disparities | 3 | 2021 | 3412 | 0.080 |
Why?
|
| Africa | 2 | 2016 | 725 | 0.080 |
Why?
|
| Prevalence | 4 | 2021 | 15832 | 0.080 |
Why?
|
| Patient Dropouts | 2 | 2012 | 411 | 0.080 |
Why?
|
| Pilot Projects | 4 | 2015 | 8725 | 0.080 |
Why?
|
| Mexico | 2 | 2023 | 771 | 0.080 |
Why?
|
| Fluoroquinolones | 1 | 2010 | 307 | 0.080 |
Why?
|
| Communicable Diseases | 1 | 2016 | 874 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2024 | 3785 | 0.070 |
Why?
|
| Psychology | 1 | 2010 | 354 | 0.070 |
Why?
|
| Skull | 1 | 1992 | 814 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 8039 | 0.070 |
Why?
|
| Social Conditions | 1 | 2008 | 119 | 0.070 |
Why?
|
| Nigeria | 1 | 2010 | 782 | 0.070 |
Why?
|
| Psychometrics | 1 | 2017 | 3061 | 0.070 |
Why?
|
| Mentors | 1 | 2012 | 671 | 0.070 |
Why?
|
| Telemedicine | 1 | 2024 | 3106 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 1731 | 0.070 |
Why?
|
| Hepatitis C | 1 | 2017 | 1596 | 0.070 |
Why?
|
| Child | 11 | 2022 | 80509 | 0.070 |
Why?
|
| Disease Management | 1 | 2017 | 2532 | 0.070 |
Why?
|
| Health Status | 1 | 2020 | 4084 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1959 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1134 | 0.070 |
Why?
|
| HIV-1 | 5 | 2010 | 6943 | 0.070 |
Why?
|
| Research Support as Topic | 1 | 2010 | 696 | 0.060 |
Why?
|
| Boston | 3 | 2009 | 9336 | 0.060 |
Why?
|
| Dopamine Antagonists | 2 | 1997 | 278 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 7476 | 0.060 |
Why?
|
| Goals | 1 | 2011 | 717 | 0.060 |
Why?
|
| Algorithms | 1 | 2006 | 14062 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 556 | 0.060 |
Why?
|
| Obstetrics | 1 | 2012 | 679 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 5889 | 0.060 |
Why?
|
| Delivery, Obstetric | 1 | 2012 | 945 | 0.060 |
Why?
|
| Capacity Building | 2 | 2020 | 266 | 0.060 |
Why?
|
| Haloperidol | 2 | 1997 | 394 | 0.060 |
Why?
|
| Marine Biology | 1 | 2004 | 17 | 0.060 |
Why?
|
| Cholera | 1 | 2011 | 754 | 0.060 |
Why?
|
| Health Services | 1 | 2010 | 756 | 0.060 |
Why?
|
| Prenatal Care | 1 | 2012 | 1157 | 0.060 |
Why?
|
| Fetus | 1 | 1992 | 1878 | 0.060 |
Why?
|
| Organizations | 2 | 2016 | 172 | 0.060 |
Why?
|
| Counseling | 2 | 2010 | 1551 | 0.060 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 503 | 0.060 |
Why?
|
| Fertility | 1 | 2009 | 768 | 0.060 |
Why?
|
| Retreatment | 1 | 2006 | 597 | 0.060 |
Why?
|
| Residence Characteristics | 2 | 2015 | 2115 | 0.060 |
Why?
|
| Mothers | 1 | 2014 | 2207 | 0.060 |
Why?
|
| Professional Role | 1 | 2007 | 314 | 0.060 |
Why?
|
| Seawater | 1 | 2004 | 126 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 791 | 0.060 |
Why?
|
| Informed Consent | 1 | 2010 | 1009 | 0.060 |
Why?
|
| Netherlands | 1 | 2008 | 2277 | 0.050 |
Why?
|
| General Surgery | 1 | 2015 | 1722 | 0.050 |
Why?
|
| Thailand | 1 | 2004 | 288 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2008 | 6304 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2009 | 560 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2009 | 1021 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2004 | 100 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2016 | 2066 | 0.050 |
Why?
|
| Patient Rights | 1 | 2004 | 126 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2017 | 10087 | 0.050 |
Why?
|
| Education, Medical | 1 | 2015 | 1746 | 0.050 |
Why?
|
| Focus Groups | 2 | 2023 | 1459 | 0.050 |
Why?
|
| Social Change | 1 | 2003 | 152 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2011 | 26337 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 986 | 0.050 |
Why?
|
| Weight Loss | 1 | 2014 | 2710 | 0.050 |
Why?
|
| Social Environment | 1 | 2007 | 1011 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 3229 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3099 | 0.050 |
Why?
|
| Prisoners | 1 | 2006 | 315 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3222 | 0.050 |
Why?
|
| Middle Aged | 15 | 2021 | 223016 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2009 | 1433 | 0.050 |
Why?
|
| Anthropology, Cultural | 1 | 2022 | 103 | 0.050 |
Why?
|
| Linear Models | 1 | 2012 | 5873 | 0.050 |
Why?
|
| Students, Medical | 1 | 2015 | 1962 | 0.050 |
Why?
|
| Civil Rights | 1 | 2022 | 129 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2024 | 751 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2003 | 365 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 1995 | 3076 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2012 | 2968 | 0.050 |
Why?
|
| Jordan | 1 | 2021 | 73 | 0.050 |
Why?
|
| Drug Resistance, Microbial | 1 | 2004 | 833 | 0.050 |
Why?
|
| Breast Feeding | 1 | 2009 | 1363 | 0.050 |
Why?
|
| Logistic Models | 3 | 2012 | 13266 | 0.050 |
Why?
|
| Young Adult | 8 | 2017 | 59849 | 0.040 |
Why?
|
| Animals | 14 | 1999 | 168730 | 0.040 |
Why?
|
| Commerce | 1 | 2006 | 611 | 0.040 |
Why?
|
| Middle East | 1 | 2021 | 237 | 0.040 |
Why?
|
| Critical Care | 2 | 2023 | 2708 | 0.040 |
Why?
|
| Hepacivirus | 2 | 2018 | 1343 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2004 | 1042 | 0.040 |
Why?
|
| Pediatrics | 1 | 2015 | 3602 | 0.040 |
Why?
|
| Kinetics | 2 | 1999 | 6272 | 0.040 |
Why?
|
| Selegiline | 1 | 1999 | 31 | 0.040 |
Why?
|
| Information Systems | 1 | 2002 | 399 | 0.040 |
Why?
|
| RNA, Viral | 3 | 2018 | 2863 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 39226 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2004 | 1476 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2004 | 811 | 0.040 |
Why?
|
| Anxiety | 2 | 2015 | 4670 | 0.040 |
Why?
|
| Drug Resistance, Viral | 1 | 2004 | 866 | 0.040 |
Why?
|
| Canada | 1 | 2004 | 2119 | 0.040 |
Why?
|
| Receptors, Dopamine D3 | 1 | 1999 | 106 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2007 | 950 | 0.040 |
Why?
|
| Synaptosomes | 1 | 1998 | 116 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2012 | 9355 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1438 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1998 | 515 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2003 | 1667 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1998 | 528 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5302 | 0.040 |
Why?
|
| Patients | 1 | 2023 | 909 | 0.030 |
Why?
|
| AIDS Vaccines | 1 | 2003 | 898 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2018 | 416 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2001 | 1801 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14644 | 0.030 |
Why?
|
| Phylogeny | 1 | 2004 | 2835 | 0.030 |
Why?
|
| Cohort Studies | 6 | 2014 | 41643 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2006 | 6320 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2004 | 1424 | 0.030 |
Why?
|
| Phencyclidine | 1 | 1996 | 59 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 1375 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2022 | 22227 | 0.030 |
Why?
|
| Travel | 1 | 2022 | 806 | 0.030 |
Why?
|
| Macaca | 1 | 1997 | 413 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 608 | 0.030 |
Why?
|
| Raclopride | 1 | 1996 | 98 | 0.030 |
Why?
|
| Hospitalization | 1 | 2016 | 10803 | 0.030 |
Why?
|
| Cebus | 1 | 1995 | 15 | 0.030 |
Why?
|
| Receptors, Serotonin | 1 | 1996 | 209 | 0.030 |
Why?
|
| Data Collection | 1 | 2004 | 3317 | 0.030 |
Why?
|
| Internet | 2 | 2004 | 3104 | 0.030 |
Why?
|
| Radioactive Tracers | 1 | 1995 | 61 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1998 | 952 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 1553 | 0.030 |
Why?
|
| Disasters | 1 | 2021 | 521 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2021 | 1573 | 0.030 |
Why?
|
| Carbon Radioisotopes | 1 | 1996 | 543 | 0.030 |
Why?
|
| Electric Injuries | 1 | 1994 | 24 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 4 | 2008 | 1914 | 0.030 |
Why?
|
| Needlestick Injuries | 1 | 1994 | 71 | 0.030 |
Why?
|
| Molecular Structure | 2 | 1996 | 1886 | 0.030 |
Why?
|
| Fluconazole | 1 | 1994 | 154 | 0.030 |
Why?
|
| Health Education | 1 | 2020 | 1060 | 0.030 |
Why?
|
| Government Agencies | 1 | 2014 | 161 | 0.030 |
Why?
|
| Cryptococcosis | 1 | 1994 | 99 | 0.030 |
Why?
|
| Time Factors | 4 | 2013 | 40109 | 0.030 |
Why?
|
| Organ Specificity | 1 | 1998 | 1964 | 0.030 |
Why?
|
| Accidents | 1 | 1994 | 164 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2001 | 1798 | 0.030 |
Why?
|
| Hospitals, Rural | 1 | 2015 | 175 | 0.030 |
Why?
|
| Aged | 10 | 2018 | 171178 | 0.030 |
Why?
|
| Nepal | 1 | 2014 | 302 | 0.030 |
Why?
|
| Teaching | 1 | 2021 | 1170 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 1996 | 3053 | 0.030 |
Why?
|
| Sputum | 2 | 2008 | 513 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 220 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1996 | 622 | 0.020 |
Why?
|
| HIV Seroprevalence | 1 | 2012 | 89 | 0.020 |
Why?
|
| Ligands | 1 | 1999 | 3273 | 0.020 |
Why?
|
| Incidence | 2 | 2011 | 21501 | 0.020 |
Why?
|
| Thiazoles | 1 | 1999 | 1529 | 0.020 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2014 | 373 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 11838 | 0.020 |
Why?
|
| Transfection | 1 | 1999 | 5742 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1995 | 1527 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2014 | 350 | 0.020 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1996 | 896 | 0.020 |
Why?
|
| Twins | 1 | 1992 | 340 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2003 | 3240 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12235 | 0.020 |
Why?
|
| Fetal Death | 1 | 1992 | 434 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 2014 | 601 | 0.020 |
Why?
|
| Inpatients | 1 | 2022 | 2564 | 0.020 |
Why?
|
| Dopamine | 1 | 1997 | 1583 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 6489 | 0.020 |
Why?
|
| Prospective Studies | 3 | 2022 | 54798 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1994 | 1145 | 0.020 |
Why?
|
| Longitudinal Studies | 3 | 2016 | 14745 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 5529 | 0.020 |
Why?
|
| Cerebellum | 1 | 1996 | 1519 | 0.020 |
Why?
|
| Physician Incentive Plans | 1 | 2009 | 165 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1879 | 0.020 |
Why?
|
| Mass Screening | 1 | 2023 | 5445 | 0.020 |
Why?
|
| Social Isolation | 1 | 2010 | 366 | 0.020 |
Why?
|
| Latvia | 1 | 2006 | 15 | 0.020 |
Why?
|
| Estonia | 1 | 2006 | 56 | 0.020 |
Why?
|
| Philippines | 1 | 2006 | 95 | 0.020 |
Why?
|
| Radiography | 1 | 1997 | 6941 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2003 | 1971 | 0.020 |
Why?
|
| Fear | 1 | 2014 | 1496 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1997 | 10723 | 0.020 |
Why?
|
| Cell Line | 1 | 1999 | 15540 | 0.020 |
Why?
|
| United States | 3 | 2021 | 72896 | 0.020 |
Why?
|
| Leadership | 1 | 2014 | 1391 | 0.020 |
Why?
|
| Mitochondria | 1 | 1998 | 3670 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2016 | 1936 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2017 | 2521 | 0.010 |
Why?
|
| Diffusion of Innovation | 1 | 2009 | 722 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 24278 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2013 | 6204 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2017 | 2386 | 0.010 |
Why?
|
| Epitopes | 2 | 2001 | 2523 | 0.010 |
Why?
|
| Genotype | 1 | 2018 | 13023 | 0.010 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2007 | 497 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2780 | 0.010 |
Why?
|
| Perception | 1 | 2010 | 1204 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4624 | 0.010 |
Why?
|
| Risk | 1 | 2015 | 9600 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 1510 | 0.010 |
Why?
|
| Length of Stay | 1 | 2016 | 6485 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2016 | 5338 | 0.010 |
Why?
|
| Information Management | 1 | 2002 | 100 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 8927 | 0.010 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2003 | 265 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 207 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 2001 | 317 | 0.010 |
Why?
|
| Acute Disease | 2 | 2001 | 7237 | 0.010 |
Why?
|
| HIV Antigens | 1 | 2001 | 328 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 213 | 0.010 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 1084 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2001 | 13402 | 0.010 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2005 | 667 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 20131 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 4849 | 0.010 |
Why?
|
| Public Health Practice | 1 | 2001 | 219 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10570 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2007 | 1448 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2776 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 2823 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8529 | 0.010 |
Why?
|
| Dizocilpine Maleate | 1 | 1996 | 171 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2002 | 960 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2001 | 6607 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2001 | 974 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1996 | 456 | 0.010 |
Why?
|
| Isotope Labeling | 1 | 1996 | 389 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1994 | 134 | 0.010 |
Why?
|
| Research | 1 | 2002 | 1974 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12056 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2006 | 12520 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 3686 | 0.010 |
Why?
|
| Base Sequence | 1 | 2001 | 12402 | 0.010 |
Why?
|
| Muscles | 1 | 1994 | 1578 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 9081 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 17595 | 0.000 |
Why?
|
| Age Factors | 1 | 2005 | 18380 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 59506 | 0.000 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 3677 | 0.000 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7416 | 0.000 |
Why?
|